%0 Journal Article
%T Assessment of Clinical Outcome of Patients With Primary Myelofibrosis Treated £¿With Ruxolitinib in the Real-World Practice | Alwan | Global Journal of Health Science | CCSE
%A Alaa Fadhil Alwan
%A Hayder Adnan Fawzi
%A Yaseen Muhialdeen Taher
%J Home | Global Journal of Health Science | CCSE
%D 2019
%R 10.5539/gjhs.v11n6p106
%X BACKGROUND: Primary myelofibrosis (PMF) is a disease that characterized by bone £¿marrow fibrosis which £¿may £¿result sometime in cytopenias and extramedullary £¿hematopoiesis causing massive £¿splenomegaly. Ruxolitinib (Rux) therapy that targeted £¿Janus Kinase-2 receptor and approved £¿for treatment of primary myelofibrosis. £¿

OBJECTIVE: evaluate the clinical £¿outcome of patients with £¿primary myelofibrosis £¿receiving Ruxolitinib treatment as £¿a compassionate use program £¿and compare this treatment with the best £¿available treatment (BAT).£¿ 

METHODS: £¿This is a retrospective case series conducted at the national £¿center of hematology /£¿£¿Mustansiriyah University. The enrollment of patients started £¿in May 2014 and ended in May £¿£¿2017. There were £¿£¿22 patients diagnosed with PMF (7 on £¿the Ruxolitinib arm and 15 on best £¿available treatment arm). The £¿treatment response £¿was evaluated according to consensus criteria £¿of IWG-MRT 2013 in primary £¿£¿myelofibrosis.

RESULTS: In this study 3 out of 7 patients on Ruxolitinib arm showed reduction in spleen size and reduction in anemia. In addition to £¿that 4 patients £¿showed clinical response specifically in spleen £¿size (with 65% reduction from baseline during the first three months of treatment). 

CONCLUSION: Rux is effective and safe to treating £¿primary myelofibrosis with £¿symptomatic splenomegaly
%U http://www.ccsenet.org/journal/index.php/gjhs/article/view/0/39418